Related Experiment Video
Updated: May 30, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer
Edgar S Diaz-Cruz1, Marina C Cabrera, Rebecca Nakles
1Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Abstract:
Genetically engineered mice along with allograft and xenograft models can be used to effectively model triple negative breast cancer both for studies of pathophysiology as well as preclinical prevention and therapeutic drug studies. In this review eight distinct genetically engineered mouse models of BRCA1 deficiency are discussed in relationship to the generation of triple negative mammary cancer. Allograft models derived from some of these genetically engineered mice are considered and xenograft models derived from breast cancers that developed from BRCA1 mutation are presented. Examples of the use of genetically engineered, allograft and xenografts models for preventive and therapeutic studies are presented.
Insights
Genetically engineered mouse models, including allograft and xenograft approaches, are crucial for studying triple-negative breast cancer (TNBC) and testing new therapies. This review highlights BRCA1-deficient models for TNBC research and drug development.
Area of Science:
- Oncology
- Genetics
- Cancer Biology
Background:
- Triple-negative breast cancer (TNBC) lacks targeted therapies, necessitating robust preclinical models.
- Genetically engineered mouse models (GEMMs) offer valuable platforms for understanding TNBC pathophysiology.
- BRCA1 deficiency is a key factor in developing certain types of TNBC.
Purpose of the Study:
- To review genetically engineered mouse models relevant to BRCA1-deficient triple-negative breast cancer.
- To discuss the application of allograft and xenograft models derived from GEMMs in TNBC research.
- To highlight the utility of these models in preclinical prevention and therapeutic drug studies.
Main Methods:
- Discussion of eight distinct genetically engineered mouse models focusing on BRCA1 deficiency.
- Consideration of allograft models derived from these GEMMs.
- Presentation of xenograft models from BRCA1-mutated breast cancers.
Main Results:
- GEMMs, allograft, and xenograft models effectively recapitulate aspects of triple-negative breast cancer.
- These models are instrumental in studying disease mechanisms and evaluating preventive strategies.
- The models facilitate preclinical testing of novel therapeutic agents for TNBC.
Conclusions:
- Genetically engineered mouse models, allograft, and xenograft models are essential tools for advancing triple-negative breast cancer research.
- BRCA1-deficient models are particularly relevant for understanding and treating specific TNBC subtypes.
- These preclinical models are critical for the development of effective prevention and treatment strategies for TNBC.
